Platelet-to-Neutrophil Ratio: A Novel Prognostic Indicator for Anti-PD-1-Based Therapy in Relapsed/Refractory Hodgkin Lymphoma and Solid Tumors

Abstract

Program cell death-1 (PD-1) blockade treatment has been shown effective in cases with relapsed/refractory classical Hodgkin Lymphoma (R/R cHL), while prognostic biomarkers remain unclear. Seventy-seven cases with R/R cHL who received immunotherapy for the first time were included. Receiver operator characteristic analysis displayed platelet-to-neutrophil ratio (PNR) as the most probable indicator among distinct inflammatory-cell ratios. Patients with high pretreatment PNR (≥ 51.6) achieved significantly higher complete response (CR) rate as compared with patients with low PNR (< 51.6), and PNR^high patients displayed significantly longer progression-free survival (PFS) versus PNR^low patients (p = 0.001). Cox analysis indicated PNR as an independent factor for prognosis (hazard ratio, 0.34, 95% CI, 0.18–0.65, p = 0.001). Among patients acquiring CR, higher PNR was associated with improved PFS and relapse-free survival. Moreover, PNR correlations with CR rate and PFS were validated in external cohort of cHL. Notably, PNR was also a strong prognostic biomarker for PFS and overall survival after anti-PD-1 combination therapy in patients with solid tumors, such as biliary tract carcinoma, gastric carcinoma, or colon cancer. In conclusion, this study for the first time reveals a correlation between pretreatment peripheral PNR and prognosis of anti-PD-1-based therapy in patients with relapsed/refractory cHL and advanced solid tumor.

Keywords

peripheral biomarker; platelet-to-neutrophil ratio / prognosis / Hodgkin lymphoma / anti-PD-1 immunotherapy

References

[1] R. L. Siegel, A. N. Giaquinto, and A. Jemal, “Cancer Statistics, 2024,” CA: A Cancer Journal for Clinicians 74, no. 1 (2024): 12-49.

[2] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer Statistics, 2022,” CA: A Cancer Journal for Clinicians 72, no. 1 (2022): 7-33.

[3] R. Alaggio, C. Amador, I. Anagnostopoulos, et al., “The 5th edition of the World Health Organization Classification of Haematolymphoid Tumors: Lymphoid Neoplasms,” Leukemia 36, no. 7 (2022): 1720-1748.

[4] P. Brice, E. de Kerviler, and J. W. Friedberg, “Classical Hodgkin Lymphoma,” Lancet 398, no. 10310 (2021): 1518-1527.

[5] M. Khan, F. Hagemeister, M. Wang, and S. Ahmed, “A Review of Pathobiology and Therapies for Classic Hodgkin Lymphoma,” Blood Reviews 55 (2022): 100949.

[6] R. T. Hoppe, R. H. Advani, W. Z. Ai, et al., “NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022,” Journal of the National Comprehensive Cancer Network: JNCCN 20, no. 4 (2022): 322-334.

[7] A. Younes, A. Santoro, M. Shipp, et al., “Nivolumab for Classical Hodgkin's Lymphoma after Failure of both Autologous Stem-Cell Transplantation and Brentuximab Vedotin: A Multicentre, Multicohort, Single-Arm Phase 2 Trial,” Lancet Oncology 17, no. 9 (2016): 1283-1294.

[8] P. Armand, A. Engert, A. Younes, et al., “Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma after Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial,” Journal of Clinical Oncology 36, no. 14 (2018): 1428-1439.

[9] S. M. Ansell, A. M. Lesokhin, I. Borrello, et al., “PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma,” New England Journal of Medicine 372, no. 4 (2015): 311-319.

[10] J. Nie, C. Wang, Y. Liu, et al., “Addition of Low-Dose Decitabine to Anti-PD-1 Antibody Camrelizumab in Relapsed/Refractory Classical Hodgkin Lymphoma,” Journal of Clinical Oncology 37, no. 17 (2019): 1479-1489.

[11] C. Hu, L. Zhao, W. Liu, et al., “Genomic Profiles and Their Associations with TMB, PD-L1 Expression, and Immune Cell Infiltration Landscapes in Synchronous Multiple Primary Lung Cancers,” Journal for ImmunoTherapy of Cancer 9, no. 12 (2021): e003773.

[12] T. A. Chan, M. Yarchoan, E. Jaffee, et al., “Development of Tumor Mutation Burden as an Immunotherapy Biomarker: Utility for the Oncology Clinic,” Annals of Oncology 30, no. 1 (2019): 44-56.

[13] P. Zhao, L. Li, X. Jiang, and Q. Li, “Mismatch Repair Deficiency/Microsatellite Instability-High as a Predictor for Anti-PD-1/PD-L1 Immunotherapy Efficacy,” Journal of Hematology & Oncology 12, no. 1 (2019): 54.

[14] X. Wang, G. Lamberti, A. Di Federico, et al., “Tumor Mutational Burden for the Prediction of PD-(L)1 Blockade Efficacy in Cancer: Challenges and Opportunities,” Annals of Oncology 35, no. 6 (2024): 508-522.

[15] H. Ouyang, B. Xiao, Y. Huang, and Z. Wang, “Baseline and Early Changes in the Neutrophil-lymphocyte Ratio (NLR) Predict Survival Outcomes in Advanced Colorectal Cancer Patients Treated with Immunotherapy,” International Immunopharmacology 123 (2023): 110703.

[16] S. Dharmapuri, U. Özbek, J. Y. Lin, et al., “Predictive Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Advanced Hepatocellular Carcinoma Patients Treated with Anti-PD-1 Therapy,” Cancer Medicine 9, no. 14 (2020): 4962-4970.

[17] C. Li, J. Wu, L. Jiang, et al., “The Predictive Value of Inflammatory Biomarkers for Major Pathological Response in Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemoimmunotherapy and Its Association with the Immune-related Tumor Microenvironment: A Multi-center Study,” Cancer Immunology, Immunotherapy 72, no. 3 (2023): 783-794.

[18] J. Cao, Q. Chen, X. Bai, et al., “Predictive Value of Immunotherapy-Induced Inflammation Indexes: Dynamic Changes in Patients with Nasopharyngeal Carcinoma Receiving Immune Checkpoint Inhibitors,” Annals of Medicine 55, no. 2 (2023): 2280002.

[19] V. Aslan, A. C. Karabörk Kılıç, A. Özet, et al., “The Role of Spleen Volume Change in Predicting Immunotherapy Response in Metastatic Renal Cell Carcinoma,” BMC cancer 23, no. 1 (2023): 1045.

[20] D. Mallardo, M. Fordellone, A. White, et al., “CD39 and LDHA Affects the Prognostic Role of NLR in Metastatic Melanoma Patients Treated with Immunotherapy,” Journal of Translational Medicine 21, no. 1 (2023): 610.

[21] F. Zheng, Q. Meng, L. Zhang, et al., “Prognostic Roles of Hematological Indicators for the Efficacy and Prognosis of Immune Checkpoint Inhibitors in Patients with Advanced Tumors: A Retrospective Cohort Study,” World Journal of Surgical Oncology 21, no. 1 (2023): 198.

[22] A. Muhammed, C. A. M. Fulgenzi, S. Dharmapuri, et al., “The Systemic Inflammatory Response Identifies Patients with Adverse Clinical Outcome from Immunotherapy in Hepatocellular Carcinoma,” Cancers (Basel) 14, no. 1 (2021): 186.

[23] Q. Huai, C. Luo, P. Song, et al., “Peripheral Blood Inflammatory Biomarkers Dynamics Reflect Treatment Response and Predict Prognosis in Non-Small Cell Lung Cancer Patients with Neoadjuvant Immunotherapy,” Cancer Science 114, no. 12 (2023): 4484-4498.

[24] Y. Pan, Y. Ma, and G. Dai, “The Prognostic Value of the Prognostic Nutritional Index in Patients with Advanced or Metastatic Gastric Cancer Treated with Immunotherapy,” Nutrients 15, no. 19 (2023): 4290.

[25] A. Pociute, M. F. Kottilingal Farook, A. Dagys, R. Kevalas, G. Laucaityte, and L. Jankauskaite, “Platelet-Derived Biomarkers: Potential Role in Early Pediatric Serious Bacterial Infection and Sepsis Diagnostics,” Journal of Clinical Medicine 11, no. 21 (2022): 6475.

[26] H. Que, Q. Fu, T. Lan, X. Tian, and X. Wei, “Tumor-associated Neutrophils and Neutrophil-targeted Cancer Therapies,” Biochimica Et Biophysica Acta (BBA)—Reviews on Cancer 1877, no. 5 (2022): 188762.

[27] R. Xue, Q. Zhang, Q. Cao, et al., “Liver Tumour Immune Microenvironment Subtypes and Neutrophil Heterogeneity.” Nature 2022; 612(7938): 141-147.

[28] J. W. Semple, J. E. Italiano,, and J. Freedman, “Platelets and the Immune Continuum.” Nature Reviews Immunology 11, no. 4 (2011): 264-274.

[29] B. D. Elzey, N. W. Schmidt, S. A. Crist, et al., “Platelet-Derived CD154 Enables T-Cell Priming and Protection against Listeria Monocytogenes Challenge.” Blood 111, no. 7 (2008): 3684-3691.

[30] C. N. Morrell, A. A. Aggrey, L. M. Chapman, and K. L. Modjeski, “Emerging Roles for Platelets as Immune and Inflammatory Cells.” Blood 123, no. 18 (2014): 2759-2767.

RIGHTS & PERMISSIONS

2025 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.